JP Morgan analyst Stephen Tusa reinstates PTC (NASDAQ:PTC) with a Neutral and announces $128 price target.
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate – A Setback in High-Risk Melanoma Treatment
Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher discontinuation rates and immune-related adverse events.